The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 16 results:
Author [ Title(Desc)] Type Year
Filters: Author is Eleftheraki, Anastasia G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Koletsa, T., Stavridi F., Bobos M., Kostopoulos I., Kotoula V., Eleftheraki A. G., et al. (2014).  alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.. BMC Clin Pathol. 14, 28.
Lakis, S., Kotoula V., Eleftheraki A. G., Batistatou A., Bobos M., Koletsa T., et al. (2014).  The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping.. Breast. 23(3), 234-43.
D
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
E
Batistatou, A., Televantou D., Bobos M., Eleftheraki A. G., Kouvaras E., Chrisafi S., et al. (2013).  Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.. Anticancer Res. 33(5), 2139-45.
Kotoula, V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A. G., Televantou D., et al. (2012).  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).. BMC Cancer. 12, 342.
H
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
I
Fountzilas, E., Kotoula V., Angouridakis N., Karasmanis I., Wirtz R. M., Eleftheraki A. G., et al. (2013).  Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.. PLoS One. 8(8), e70429.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
P
Pavlakis, K., Bobos M., Batistatou A., Kotoula V., Eleftheraki A. G., Stofas A., et al. (2015).  p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab.. Pathol Oncol Res. 21(2), 273-82.
Gogas, H., Dafni U., Karina M., Papadimitriou C., Batistatou A., Bobos M., et al. (2012).  Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.. Breast Cancer Res Treat. 132(2), 609-19.
Koumarianou, A., Tzeveleki I., Mekras D., Eleftheraki A. G., Bobos M., Wirtz R., et al. (2014).  Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.. Anticancer Res. 34(9), 4949-62.
Pentheroudakis, G., Kotoula V., Eleftheraki A. G., Tsolaki E., Wirtz R. M., Kalogeras K. T., et al. (2013).  Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).. PLoS One. 8(7), e70634.
Pentheroudakis, G., Batistatou A., Kalogeras K. T., Kronenwett R., Wirtz R. M., Bournakis E., et al. (2011).  Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.. Breast Cancer Res Treat. 127(1), 179-93.
T
Fountzilas, G., Christodoulou C., Bobos M., Kotoula V., Eleftheraki A. G., Xanthakis I., et al. (2012).  Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.. J Transl Med. 10, 212.
V
Iliadis, G., Kotoula V., Chatzisotiriou A., Televantou D., Eleftheraki A. G., Lambaki S., et al. (2012).  Volumetric and MGMT parameters in glioblastoma patients: survival analysis.. BMC Cancer. 12, 3.
X
Pectasides, D., Papaxoinis G., Kalogeras K. T., Eleftheraki A. G., Xanthakis I., Makatsoris T., et al. (2012).  XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.. BMC Cancer. 12, 271.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.